Novartis AG
NVS
150.20
-0.42
-0.28%
Novartis AG
US · NVS
#65 by market cap
Listed 1970
150.20
-0.42
-0.28%
Live - 5344 symbols - heartbeat 408s ago
· 2026-10-20 08:17
Analyst consensus 4 analysts
Buy
Avg price target 168.67 +12.3%
Price target rangecurrent 150.20
Low156.00
Avg168.67
High180.00
Buy 75%
Hold 25%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-06 | Morgan Stanley | -- | Buy | 156.00 |
| 2026-10-05 | BofA Securities | -- | Buy | -- |
| 2026-09-08 | TD Cowen | -- | Hold | 180.00 |
| 2026-09-07 | BofA Securities | -- | Buy | 180.87 |
| 2026-09-01 | BofA Securities | -- | Buy | 172.75 |
| 2026-07-27 | TD Cowen | -- | Hold | 180.00 |
| 2026-07-24 | Argus Research | -- | Buy | 170.00 |
| 2026-07-21 | BofA Securities | -- | Buy | -- |
| 2026-06-11 | TD Cowen | -- | Hold | 180.00 |
| 2026-06-11 | BofA Securities | -- | Buy | 173.29 |
| 2026-06-04 | Argus Research | -- | Buy | 160.00 |
| 2026-05-18 | TD Cowen | -- | Hold | 148.08 |
| 2026-03-27 | BofA Securities | -- | Buy | 175.37 |
| 2026-03-26 | Morgan Stanley | -- | Buy | 170.00 |
| 2026-03-24 | BofA Securities | -- | Buy | 176.12 |
| 2026-03-23 | BofA Securities | -- | Buy | 177.65 |
| 2026-03-19 | Bernstein | -- | Hold | -- |
| 2026-02-17 | TD Cowen | -- | Hold | 180.00 |
| 2026-02-16 | TD Cowen | -- | Hold | 180.00 |
| 2026-01-06 | Barclays | -- | Hold | -- |
| 2025-12-10 | HSBC | -- | Sell | 112.00 |
| 2025-12-03 | Morgan Stanley | -- | Buy | 143.00 |
| 2025-11-20 | J.P. Morgan | -- | Hold | -- |
| 2025-11-10 | TD Cowen | -- | Hold | 140.00 |
| 2025-10-02 | TD Cowen | -- | Hold | 140.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Hold
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-27 | -- | -- | -- |
| 2026/Q2 | 2026-07-21 | -- | ±5.48% | +2.88% (in line) |
| 2026/Q1 | 2026-04-28 | -- | ±4.03% | +0.91% (in line) |
| 2025/Q4 | 2026-02-04 | -- | ±4.51% | +2.04% (in line) |
| 2025/Q3 | 2025-10-28 | -- | ±3.78% | -4.42% (beat) |
| 2025/Q2 | 2025-07-17 | -- | ±3.98% | -3.25% (in line) |
| 2025/Q1 | 2025-04-29 | -- | ±5.42% | +0.73% (in line) |
| 2024/Q4 | 2025-01-31 | -- | ±5.58% | -0.03% (in line) |
| 2024/Q1 | 2024-04-23 | -- | ±5.89% | +2.27% (in line) |
| 2023/Q4 | 2024-01-31 | -- | ±4.64% | -3.97% (in line) |
| 2023/Q3 | 2023-10-24 | -- | ±5.08% | +0.23% (in line) |
| 2023/Q2 | 2023-07-18 | -- | ±4.85% | +4.57% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-20 08:17:48 · For reference only, not investment advice and not tailored to your situation.
Novartis AG discussion 0 comments